Johnson & Johnson (NYSE:JNJ) was the target of a large decline in short interest during the month of August. As of August 31st, there was short interest totalling 20,092,691 shares, a decline of 13.3% from the August 15th total of 23,185,697 shares. Based on an average trading volume of 6,945,621 shares, the days-to-cover ratio is presently 2.9 days. Currently, 0.7% of the shares of the stock are short sold.

In other Johnson & Johnson news, CAO Ronald A. Kapusta sold 2,935 shares of Johnson & Johnson stock in a transaction that occurred on Friday, July 22nd. The stock was sold at an average price of $125.01, for a total value of $366,904.35. Following the sale, the chief accounting officer now owns 28,660 shares of the company’s stock, valued at approximately $3,582,786.60. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink. Also, VP Dominic J. Caruso sold 41,146 shares of Johnson & Johnson stock in a transaction that occurred on Tuesday, July 26th. The stock was sold at an average price of $125.01, for a total value of $5,143,661.46. Following the completion of the sale, the vice president now directly owns 157,819 shares in the company, valued at approximately $19,728,953.19. The disclosure for this sale can be found here. 0.11% of the stock is owned by company insiders.

Several large investors have recently modified their holdings of the stock. Avalon Advisors LLC raised its position in Johnson & Johnson by 32.7% in the first quarter. Avalon Advisors LLC now owns 410,880 shares of the company’s stock worth $44,457,000 after buying an additional 101,250 shares during the period. Fisher Asset Management LLC raised its position in Johnson & Johnson by 0.4% in the first quarter. Fisher Asset Management LLC now owns 10,854,263 shares of the company’s stock worth $1,195,923,000 after buying an additional 38,299 shares during the period. British Columbia Investment Management Corp raised its position in Johnson & Johnson by 1.0% in the second quarter. British Columbia Investment Management Corp now owns 1,649,232 shares of the company’s stock worth $200,052,000 after buying an additional 17,000 shares during the period. Legal & General Group Plc raised its position in Johnson & Johnson by 1.7% in the first quarter. Legal & General Group Plc now owns 13,449,262 shares of the company’s stock worth $1,455,269,000 after buying an additional 226,357 shares during the period. Finally, Investec Asset Management LTD raised its position in Johnson & Johnson by 49.2% in the first quarter. Investec Asset Management LTD now owns 5,050,411 shares of the company’s stock worth $546,454,000 after buying an additional 1,665,644 shares during the period. 65.31% of the stock is owned by institutional investors and hedge funds.

JNJ has been the topic of several analyst reports. Zacks Investment Research raised Johnson & Johnson from a “hold” rating to a “buy” rating and set a $133.00 target price on the stock in a research report on Tuesday, September 13th. Jefferies Group cut their target price on Johnson & Johnson from $119.00 to $115.00 and set a “hold” rating on the stock in a research report on Tuesday, September 13th. Leerink Swann reissued a “buy” rating on shares of Johnson & Johnson in a research report on Sunday, September 11th. BTIG Research reissued a “neutral” rating on shares of Johnson & Johnson in a research report on Wednesday, September 7th. Finally, Vetr raised Johnson & Johnson from a “hold” rating to a “buy” rating and set a $124.21 target price on the stock in a research report on Monday, August 22nd. One analyst has rated the stock with a sell rating, eleven have issued a hold rating and twelve have given a buy rating to the stock. The company currently has an average rating of “Hold” and a consensus target price of $119.10.

Johnson & Johnson (NYSE:JNJ) opened at 118.25 on Monday. Johnson & Johnson has a one year low of $89.90 and a one year high of $126.07. The stock has a 50 day moving average price of $121.42 and a 200-day moving average price of $115.71. The firm has a market capitalization of $323.52 billion, a price-to-earnings ratio of 22.04 and a beta of 0.61.

Johnson & Johnson (NYSE:JNJ) last issued its quarterly earnings data on Tuesday, July 19th. The company reported $1.74 earnings per share for the quarter, beating the Zacks’ consensus estimate of $1.68 by $0.06. Johnson & Johnson had a return on equity of 24.70% and a net margin of 20.97%. The business earned $18.50 billion during the quarter, compared to analysts’ expectations of $17.98 billion. On average, analysts predict that Johnson & Johnson will post $6.69 earnings per share for the current fiscal year.

The company also recently disclosed a quarterly dividend, which was paid on Tuesday, September 6th. Stockholders of record on Tuesday, August 23rd were paid a $0.80 dividend. The ex-dividend date was Friday, August 19th. This represents a $3.20 dividend on an annualized basis and a dividend yield of 2.71%. Johnson & Johnson’s payout ratio is presently 60.15%.

Johnson & Johnson Company Profile

Johnson & Johnson is a holding company, which is engaged in the research and development, manufacture and sale of a range of products in the healthcare field. The Company’s segments include Consumer, Pharmaceutical and Medical Devices. The Consumer segment includes a range of products used in the baby care, oral care, skin care, over-the-counter pharmaceutical, women’s health and wound care markets.

5 Day Chart for NYSE:JNJ

Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with Analyst Ratings Network's FREE daily email newsletter.